FDA approves Ultragenyx gene therapy for rare childhood disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St set to open lower after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 15.73 -0.22 (1.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.95 | 52 Week High | $117.12 | |||
| Open | $15.92 | 52 Week Low | $46.52 | |||
| Day High | $15.94 | P/E | N/A | |||
| Day Low | $15.50 | EPS | $-1.97 | |||
| Volume | 173,574 | |||||
